- Previous Close
13.58 - Open
13.14 - Bid 11.42 x 300
- Ask 11.87 x 800
- Day's Range
10.92 - 13.35 - 52 Week Range
1.80 - 25.92 - Volume
881,368 - Avg. Volume
4,755,805 - Market Cap (intraday)
101.695M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.02 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.83
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company develops EIP200 for central nervous system which is in preclinical trials. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
www.cervomed.comRecent News: CRVO
View MorePerformance Overview: CRVO
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRVO
View MoreValuation Measures
Market Cap
118.18M
Enterprise Value
79.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.01
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-167.29%
Return on Assets (ttm)
-42.95%
Return on Equity (ttm)
-69.95%
Revenue (ttm)
9.74M
Net Income Avi to Common (ttm)
-16.29M
Diluted EPS (ttm)
-2.02
Balance Sheet and Cash Flow
Total Cash (mrq)
38.92M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-10.69M